MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma
Overview
Authors
Affiliations
The mechanisms by which breast cancers progress from relatively indolent ductal carcinoma (DCIS) to invasive ductal carcinoma (IDC) are not well understood. However, this process is critical to the acquisition of metastatic potential. MAPK-interacting serine/threonine-protein kinase 1 (MNK1) signaling can promote cell invasion. NODAL, a morphogen essential for embryogenic patterning, is often reexpressed in breast cancer. Here we describe a MNK1/NODAL signaling axis that promotes DCIS progression to IDC. We generated MNK1 knockout (KO) or constitutively active MNK1 (caMNK1)-expressing human MCF-10A-derived DCIS cell lines, which were orthotopically injected into the mammary glands of mice. Loss of MNK1 repressed NODAL expression, inhibited DCIS to IDC conversion, and decreased tumor relapse and metastasis. Conversely, caMNK1 induced NODAL expression and promoted IDC. The MNK1/NODAL axis promoted cancer stem cell properties and invasion . The MNK1/2 inhibitor SEL201 blocked DCIS progression to invasive disease . In clinical samples, IDC and DCIS with microinvasion expressed higher levels of phospho-MNK1 and NODAL versus low-grade (invasion-free) DCIS. Cumulatively, our data support further development of MNK1 inhibitors as therapeutics for preventing invasive disease. SIGNIFICANCE: These findings provide new mechanistic insight into progression of ductal carcinoma and support clinical application of MNK1 inhibitors to delay progression of indolent ductal carcinoma to invasive ductal carcinoma.
Blocking tumor-intrinsic MNK1 kinase restricts metabolic adaptation and diminishes liver metastasis.
Preston S, Dahabieh M, Flores Gonzalez R, Goncalves C, Richard V, Leibovitch M Sci Adv. 2024; 10(37):eadi7673.
PMID: 39270021 PMC: 11397505. DOI: 10.1126/sciadv.adi7673.
The role of eIF4F-driven mRNA translation in regulating the tumour microenvironment.
Bartish M, Abraham M, Goncalves C, Larsson O, Rolny C, del Rincon S Nat Rev Cancer. 2023; 23(6):408-425.
PMID: 37142795 DOI: 10.1038/s41568-023-00567-5.
An Aptamer against MNK1 for Non-Small Cell Lung Cancer Treatment.
Carrion-Marchante R, Pinto-Diez C, Klett-Mingo J, Palacios E, Barragan-Usero M, Perez-Morgado M Pharmaceutics. 2023; 15(4).
PMID: 37111758 PMC: 10146192. DOI: 10.3390/pharmaceutics15041273.
Huang Y, Luo J, Zhang Y, Zhang T, Fei X, Chen L Comput Struct Biotechnol J. 2023; 21:1510-1522.
PMID: 36851918 PMC: 9957794. DOI: 10.1016/j.csbj.2023.02.001.
Chen W, Wang G, Zhang G Cancer Biol Med. 2022; 19(10).
PMID: 36350000 PMC: 9630521. DOI: 10.20892/j.issn.2095-3941.2022.0440.